Oregon State University Researchers Discover Novel Drug Delivery Platform for Alzheimer’s and Brain Disorders
Researchers at Oregon State University have developed a method to deliver anti-inflammatory medicines across the blood-brain barrier, offering new possibilities for treating a range of conditions, including Alzheimer’s disease, multiple sclerosis, Parkinson’s disease, and cancer cachexia.
The breakthrough involves specially designed nanoparticles, which are incredibly small, measuring no more than 100 billionths of a meter. These nanoparticles were tested in mice and successfully delivered a drug to the hypothalamus, a key part of the brain responsible for regulating essential bodily functions such as temperature, sleep cycles, hormone production, and hunger.
The study focused on cancer cachexia, a severe condition that causes weight loss and muscle wasting in patients with advanced cancers, particularly those affecting the ovaries, stomach, lungs, and pancreas. Cachexia can also result from chronic conditions such as renal failure, Crohn’s disease, rheumatoid arthritis, and HIV. It affects up to 80% of cancer patients and can be fatal in up to 30% of those who develop it.
In patients with cachexia, inflammation in the hypothalamus disrupts appetite regulation and metabolism. Traditional treatments struggle to reach the hypothalamus due to the blood-brain barrier, which is designed to protect the brain from harmful substances. This barrier makes it difficult for therapeutic agents to pass through and reach the brain. However, the newly developed nanoparticles successfully crossed the blood-brain barrier and targeted specific cells in the hypothalamus responsible for inflammation, delivering an IRAK4 inhibitor that reduces inflammation.
The researchers observed significant improvements in the mice, including a 94% increase in food intake, and the preservation of both body weight and muscle mass. The potential of these nanocarriers extends beyond cancer cachexia, offering new treatment avenues for neurological conditions marked by brain inflammation, such as Alzheimer’s disease and multiple sclerosis.
